{"generic":"Diphtheria, Tetanus, Pertussis, Hepatitis B, and Polio Vaccine","drugs":["Diphtheria, Tetanus, Pertussis, Hepatitis B, and Polio Vaccine","Pediarix"],"mono":{"0":{"id":"928469-s-0","title":"Generic Names","mono":"Diphtheria, Tetanus, Pertussis, Hepatitis B, and Polio Vaccine"},"1":{"id":"928469-s-1","title":"Dosing and Indications","sub":{"1":{"id":"928469-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Diphtheria, pertussis and tetanus triple and polio vaccination - Hepatitis B vaccination:<\/b> (6 weeks to younger than 7 years)  starting at 2 months, 0.5 mL IM at 6- to 8-week intervals for 3 doses (8-week intervals preferred); can be started as early as 6 weeks of age<\/li><li><b>Diphtheria, pertussis and tetanus triple and polio vaccination - Hepatitis B vaccination:<\/b> (6 weeks to younger than 7 years) can be given for series completion in those who received 1 or 2 doses of hepatitis B vaccine (Recombinant) or 1 or 2 doses of Infanrix(R) or IPV, and are scheduled to receive the other vaccine components of Pediarix(R); not indicated as the fourth dose of IPV or the fourth and fifth dose of DTaP<\/li><li><b>Diphtheria, pertussis and tetanus triple and polio vaccination - Hepatitis B vaccination:<\/b> (6 weeks to younger than 7 years) 3 doses can be administered to infants born to a hepatitis B surface antigen (HBsAg)-positive woman or whose HBsAg status is unknown; it is acceptable to administer DTaP-HepB-IPV (Pediarix(R)) following the birth dose of single antigen HepB vaccine resulting in a 4-dose HepB series (guideline dosing)<\/li><\/ul>"},"3":{"id":"928469-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Diphtheria, pertussis and tetanus triple and polio vaccination - Hepatitis B vaccination<br\/>"}}},"3":{"id":"928469-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928469-s-3-9","title":"Contraindications","mono":"<ul><li>allergic reaction, severe (eg, anaphylaxis), after a previous dose of any diphtheria toxoid-, tetanus toxoid-, pertussis antigen-, hepatitis B-, or poliovirus-containing vaccine, or to any vaccine component, including yeast, neomycin, and polymyxin B<\/li><li>encephalopathy (eg, coma, decreased level of consciousness, prolonged seizures) within 7 days of administration of a previous pertussis-containing vaccine that is not attributable to another identifiable cause<\/li><li>progressive neurologic disorder (eg, infantile spasms, uncontrolled epilepsy, or progressive encephalopathy); defer vaccination until neurologic status is clarified and stabilized<\/li><\/ul>"},{"id":"928469-s-3-10","title":"Precautions","mono":"<ul><li>acute illness with or without fever, moderate or severe; defer vaccination unless the benefit of protection outweighs the risk of an adverse reaction<\/li><li>children at high risk for seizures; an antipyretic medication, given at the time of vaccination and for 24 hours post-vaccination, may reduce risk of fever<\/li><li>collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours of receipt of pertussis-containing vaccine; evaluate benefit\/risk prior to administration<\/li><li>fever of 40.5 degrees C (105 degrees F) or greater within 48 hours of receipt of pertussis-containing vaccine, not due to another identifiable cause; evaluate benefit\/risk prior to administration<\/li><li>Guillain-Barre syndrome within 6 weeks of previous tetanus toxoid-containing vaccination<\/li><li>hypersensitivity reaction, arthus-type, after a previous tetanus-toxoid-containing vaccine; defer vaccination until at least 10 years since last tetanus-toxoid-containing vaccine<\/li><li>latex sensitivity; tip cap of the prefilled syringes may contain natural latex rubber<\/li><li>persistent, inconsolable crying lasting for 3 hours or more, occurring within 48 hours of receipt of pertussis-containing vaccine; evaluate benefit\/risk prior to administration<\/li><li>pregnancy; can be administered if there is a risk for exposure to wild-type poliovirus infection<\/li><li>premature infants; apnea has been observed following intramuscular vaccination; evaluate benefit\/risk prior to administration<\/li><li>revaccination in patients with unknown vaccination history; after the fourth and fifth DTaP dose an increased rate of adverse events may occur; serologic testing may be indicated<\/li><li>seizures with or without fever occurring within 3 days of receipt of pertussis-containing vaccine; evaluate benefit\/risk prior to administration<\/li><li>syncope, possibly accompanied by transient neurological signs (eg, visual disturbance, paresthesia, tonic-clonic limb movements), may occur<\/li><li>report suspected adverse effects to the Vaccine Adverse Events Reporting System (VAERS) at 1-800-822-7967 or www.vaers.hhs.gov<\/li><\/ul>"},{"id":"928469-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"928469-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"928469-s-4","title":"Drug Interactions","sub":{"1":{"id":"928469-s-4-14","title":"Major","mono":"<ul>Cyclosporine (theoretical)<\/ul>"},"2":{"id":"928469-s-4-15","title":"Moderate","mono":"<ul><li>Chloramphenicol (probable)<\/li><li>Meningococcal Vaccine, Tetanus Toxoid Conjugate Quadrivalent (established)<\/li><\/ul>"}}},"5":{"id":"928469-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Erythema at injection site (24.9% to 40.1%), Injection site edema (17.3% to 28.7%), Injection site pain (31.2% to 36.1%)<\/li><li><b>Gastrointestinal:<\/b>Loss of appetite (26.2% to 30.6%)<\/li><li><b>Neurologic:<\/b>Somnolence (40.9% to 57.2%)<\/li><li><b>Psychiatric:<\/b>Irritability (60.5% to 64.9%)<\/li><li><b>Other:<\/b>Fever (27.9% to 38.8%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Cyanosis<\/li><li><b>Immunologic:<\/b>Anaphylaxis<\/li><li><b>Neurologic:<\/b>Encephalitis, Seizure, Febrile and afebrile (0.07 to 0.14 per 1000 doses)<\/li><li><b>Psychiatric:<\/b>Crying, excessive<\/li><li><b>Respiratory:<\/b>Bronchiolitis<\/li><li><b>Other:<\/b>Angioedema, Death, Sudden infant death syndrome<\/li><\/ul>"},"6":{"id":"928469-s-6","title":"Drug Name Info","sub":[{"id":"928469-s-6-17","title":"US Trade Names","mono":"Pediarix<br\/>"},{"id":"928469-s-6-18","title":"Synonyms","mono":"<ul><li>DTaP, Hepatitis B, and Polio Vaccine<\/li><li>Diphtheria, Tetanus Toxoid, Acellular Pertussis Absorbed, Hepatitis B (Recombinant), and Inactivated Poliovirus Vaccine<\/li><li>DTaP-HepB-IPV - Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B and Inactivated Poliovirus Vaccine<\/li><\/ul>"},{"id":"928469-s-6-19","title":"Class","mono":"Vaccine<br\/>"},{"id":"928469-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}]},"7":{"id":"928469-s-7","title":"Mechanism Of Action","mono":"<ul><li>Systemic: Diphtheria: Following intramuscular injection, diphtheria toxoid induces the formation of neutralizing antibodies to diphtheria toxin.<\/li><li>Tetanus: Following intramuscular injection, tetanus toxoid induces the formation of neutralizing antibodies to tetanus toxin.<\/li><li>Pertussis: Following intramuscular injection, acellular pertussis vaccine induces the formation of several antibodies thought to be clinically protective. The levels of antibody necessary for protection have not been determined.<\/li><li>Hepatitis B: Following intramuscular injection, antibody formation against HBsAg are recognized.<\/li><li>Inactivated Poliovirus Vaccine: Following intramuscular injection, IPV induces the production of neutralizing antibodies against each poliovirus serotype.<\/li><li>According to the Center for Disease Control (CDC), hepatitis B vaccine is recognized as the first anti-cancer vaccine because it can prevent primary liver cancer. A clear link has been demonstrated between chronic hepatitis B infection and the occurrence of hepatocellular carcinoma.<\/li><\/ul>"},"9":{"id":"928469-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/><ul><li>IM only; do not administer SUBQ, IV, or intradermally<\/li><li>may be administered concomitantly with Haemophilus influenzae type B conjugate and pneumococcal vaccines in separate syringes and at separate injection sites<\/li><\/ul><\/li><li><b>Intramuscular<\/b><br\/><ul><li>shake prefilled syringe well before use; do not use if resuspension does not occur with vigorous shaking<\/li><li>attach a sterile needle to syringe for IM injection<\/li><li>administer concurrent injectable vaccines using separate syringe and at different injection site; do not mix with any other vaccine in same syringe<\/li><li>administer in the anterolateral aspects of the thigh in children younger than 1 year or in the deltoid muscle in older children; do not inject in the gluteal area or areas where there may be a major nerve trunk; gluteal injections may result in suboptimal hepatitis B immune response<\/li><\/ul><\/li><\/ul>"},"13":{"id":"928469-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause an injection site reaction or fever.<\/li><li>Inform caregiver of the importance of the child receiving the entire series of vaccinations. If a dose is missed, another appointment should be scheduled as soon as possible.<\/li><\/ul>"}}}